Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Erik M Kelly , Donald E Cutlip Added: 3 years ago
Diabetes mellitus is one of the most common chronic diseases, affecting >30 million people in the US and 422 million worldwide.1,2 Alarmingly, both the incidence and prevalence of type 2 diabetes have doubled in the US since 1990.3 This is driven by an aging population, obesity, physical inactivity, and prolonged survival in those with diabetes, among other factors. It is estimated that… View more
Research Area(s) / Expertise:

Cardiomyopathy

Heart Failure

Job title: Distinguished Hersey Professor of Medicine, MACC
Personal History Dr Braunwald is an Austrian-born American cardiologist. He was born on August 15, 1929 to Jewish parents and moved to the United States in 1939.1, 3 “I had an idyllic childhood there with an excellent school and tutors in English and piano,” he says.6 He has a younger brother who became a haematologist.1 Music is one of Dr Braunwald’s passions. He is also a keen traveler:… View more
Author(s): Stephen Ku , Steven V Edelman Added: 3 years ago
Cardiovascular disease is an important cause of morbidity and mortality in patients with type 1 and especially type 2 diabetes mellitus.1,2 Data from prospective studies suggest that diabetes is associated with a two to fourfold excess risk of coronary heart disease and coronary death.3–5 It was therefore hoped that controlling hyperglycemia would reduce cardiovascular disease incidence and… View more
Author(s): Mikhail Kosiborod Added: 6 years ago
Mikhail Kosiborod discusses the CVD-REAL 2 study - Lower Risk of Cardiovascular Events and Death Associated With Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs. Filmed on-site at the American College of Cardiology congress 2018 in Orlando, USA. View more
Author(s): Muthiah Vaduganathan Added: 3 years ago
In this video, Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US) shares the findings from the EMPA-REG OUTCOME trial. The goal of the trial was to assess the cardiovascular (CV) safety of empagliflozin, a sodium–glucose cotransporter 2 (SGLT-2) inhibitor, in patients with type 2 diabetes mellitus (T2DM) at high risk for CV events. Questions: 1. What is the background of… View more
Research Area(s) / Expertise:

Hypertension

Heart Failure

Emeritus Professor of Medicine - Cordoba National University Director - Instituto DAMIC-Fundación Rusculleda, Córdoba, Argentina Fellow of the European Society of Cardiology (FESC) Fellow of the American College of Cardiology (FACC) Past President - International Society of Cardiovascular Pharmacology DrFelipe Martínez is on the Editorial Board of European Cardiology Review. View more
Author(s): Carrie Eshelbrenner , Karina Vasquez , Liberty O Yanze , et al Added: 3 years ago
Cardiologists in general are strong advocates of evidence-based medicine, due to the critical nature of ischemic heart disease in patients. The use of up-to-date scientific evidence from research is paramount as the basis for making many medical decisions. There are three major advantages to using this approach. First, it offers some of the most objective ways to determine and maintain consistent… View more